Mutual of America Capital Management LLC Takes Position in ADMA Biologics, Inc. (NASDAQ:ADMA)

Mutual of America Capital Management LLC purchased a new position in ADMA Biologics, Inc. (NASDAQ:ADMA) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 35,056 shares of the biotechnology company’s stock, valued at approximately $701,000.

Several other institutional investors and hedge funds also recently bought and sold shares of ADMA. Hollencrest Capital Management purchased a new stake in ADMA Biologics in the 3rd quarter valued at about $30,000. Quest Partners LLC bought a new stake in shares of ADMA Biologics in the second quarter valued at about $29,000. EntryPoint Capital LLC bought a new position in ADMA Biologics during the 1st quarter worth about $31,000. USA Financial Formulas grew its holdings in ADMA Biologics by 8.6% during the 3rd quarter. USA Financial Formulas now owns 6,817 shares of the biotechnology company’s stock worth $136,000 after acquiring an additional 539 shares in the last quarter. Finally, CWM LLC raised its holdings in shares of ADMA Biologics by 114.2% in the 2nd quarter. CWM LLC now owns 8,192 shares of the biotechnology company’s stock valued at $92,000 after purchasing an additional 4,367 shares in the last quarter. 75.68% of the stock is owned by hedge funds and other institutional investors.

ADMA Biologics Stock Up 1.6 %

Shares of ADMA opened at $21.82 on Wednesday. ADMA Biologics, Inc. has a one year low of $3.60 and a one year high of $23.64. The stock has a market capitalization of $5.16 billion, a price-to-earnings ratio of 77.04 and a beta of 0.64. The company has a debt-to-equity ratio of 0.48, a quick ratio of 3.26 and a current ratio of 7.09. The stock has a 50 day moving average price of $18.92 and a 200 day moving average price of $15.05.

ADMA Biologics (NASDAQ:ADMA) last announced its quarterly earnings results on Thursday, November 7th. The biotechnology company reported $0.15 earnings per share for the quarter, beating analysts’ consensus estimates of $0.13 by $0.02. The business had revenue of $119.84 million during the quarter, compared to analysts’ expectations of $107.25 million. ADMA Biologics had a net margin of 17.80% and a return on equity of 53.20%. During the same period last year, the business earned $0.01 earnings per share. Equities research analysts forecast that ADMA Biologics, Inc. will post 0.52 earnings per share for the current fiscal year.

Analysts Set New Price Targets

Several equities analysts recently issued reports on ADMA shares. Cantor Fitzgerald reissued an “overweight” rating and set a $20.00 price objective on shares of ADMA Biologics in a report on Friday, September 20th. HC Wainwright increased their target price on ADMA Biologics from $18.00 to $26.00 and gave the company a “buy” rating in a research report on Friday, November 8th. Finally, Raymond James boosted their price target on ADMA Biologics from $18.00 to $25.00 and gave the stock a “strong-buy” rating in a research report on Friday, November 8th.

Insiders Place Their Bets

In other ADMA Biologics news, Director Lawrence P. Guiheen sold 9,000 shares of the stock in a transaction on Monday, September 9th. The stock was sold at an average price of $18.47, for a total transaction of $166,230.00. Following the sale, the director now owns 153,941 shares in the company, valued at approximately $2,843,290.27. This represents a 5.52 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, Director Jerrold B. Grossman sold 136,861 shares of the business’s stock in a transaction on Thursday, August 29th. The shares were sold at an average price of $17.27, for a total value of $2,363,589.47. Following the completion of the transaction, the director now owns 467,305 shares of the company’s stock, valued at $8,070,357.35. This trade represents a 22.65 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 185,011 shares of company stock valued at $3,255,204. 3.70% of the stock is owned by corporate insiders.

ADMA Biologics Profile

ADMA Biologics, Inc, a biopharmaceutical company, engages in developing, manufacturing, and marketing specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States and internationally. The company offers BIVIGAM, an intravenous immune globulin (IVIG) product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B.